Merck Acquires Terns Pharma for $6.7 Billion to Bolster Oncology Pipeline

Merck & Co. has reached a definitive agreement to acquire biotech firm Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, or $53.00 per share in cash. This strategic move is designed to significantly expand Merck's oncology portfolio, specifically adding a promising leukemia drug candidate to its clinical pipeline. Following the announcement, Merck's (MRK) stock price rose as investors reacted positively to the company's expansion efforts. The acquisition comes as Merck prepares for the upcoming "patent cliff" for its blockbuster cancer therapy, Keytruda, which is currently its top-selling product. By integrating Terns Pharma's assets, Merck aims to secure its market leadership in the high-growth cancer treatment sector and ensure long-term revenue sustainability. While analysts suggest the deal may still attract interest from rival bidders, it underscores Merck's aggressive pursuit of growth through strategic M&A.